NCT02808442View on ClinicalTrials.gov

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

September 17, 2020

Study Completion Date

November 4, 2020

Conditions
Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

UCART19

Trial Locations (6)

19104

Children's Hospital of Philadelphia, Philadelphia

75019

Hôpital Robert-Debré, Paris

75390

University of Texas Southwestern Medical Center, Dallas

90027

Children's Hospital Los Angeles, Los Angeles

08950

Hospital San Juan De Dios, Barcelona

Unknown

UCL Great Ormond Hospital, London

All Listed Sponsors
collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER

NCT02808442 - Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter